Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured over RMB 100 million (USD 15.7 million) in a Series A+ financing round. The funding, led by Dachen Caizhi Fortunevc with additional contributions from Wuxi Zhaoze Lifeng Investment, is earmarked for the research and development of spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) products, as well as for general company operations.
Global Neuroregulatory Market Growth
Amidst the backdrop of a burgeoning global neuroregulatory market, which is projected to expand from USD 5.8 billion in 2020 to between USD 8-10 billion by 2025, Leadinno’s investment in SCS technology is particularly strategic. Spinal cord stimulation is expected to account for over 50% of this market, underscoring the potential for significant returns on investment in this therapeutic area.
Leadinno’s SpineInno Product Line
Leadinno has already made strides with its SpineInno spinal minimally invasive product line. Notably, the SpineInno-TOP intervertebral foramen mirror product system and SpineInno-UBE, a dual channel endoscopic product system, have received regulatory approval in China. The company anticipates that its SpineInno-SIP laminoscopic surgery system and SpineInno-DLA large channel surgical system will gain approval in the first quarter of 2024, further solidifying its position in the market.-Fineline Info & Tech
